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"And if a woman have an issue, and her issue
in her flesh be blood, she shall be put apart
seven days: and whosoever toucheth her shall
be unclean until the even".
Leviticus, Chi5, V 19.
Since ancient times menstruation has been very much a taboo subject, poorly
understood and enshrouded in mystery. However, over the years much interest has
been aroused by this monthly endometrial shedding, partly out of a desire to
discover something of its underlying mechanisms, but also as a result of the
vast clinical problem that disorders of menstruation can present, for it has
been estimated that excessive menstrual blood loss may affect up to 20% of women
during their reproductive years (Jacobs et al, 1965; Hallberg et al, 1966).
Heavy menstrual bleeding, or menorrhagia, may be the result of organic
diseases such as endometrial polyps or fibroids, but in the majority of
instances, no such underlying lesion can be found, in which case the diagnosis
of dysfunctional uterine bleeding can be made (Novak et al, 1965). In some
circumstances, and especially at the extremes of the reproductive career, this
dysfunctional bleeding may be the result of a disturbance of ovarian function
(Fraser et al, 1973; Van Look et al, 1977), however, in most women with regular
but heavy periods, no impairment of the hypothalamo - pituitary - ovarian axis
can be demonstrated (Haynes et al, 1979). In consequence, much recent work has
focussed on the endometrium itself, for it is possible that local factors may
play an important part in the mechanisms controlling menstruation and its
disorders.
Observing the growth and degeneration of endometrial explants in the
anterior chamber of the eye of the monkey, Markee (1940) suggested that the
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initial process occurring at the onset of menstruation was one of intense
vasoconstriction of the spiral arterioles, with accompanying vasodilatation of
the surrounding vessels, and with the discovery that the endometrium contains
large quantities of the prostaglandins E2 and F2 <(Pickles et al, 1965), the
hypothesis that these vasoactive compounds may contribute to the control of
menstrual blood loss could be proposed.
It is now evident that excessive menstrual blood loss is associated with
changes in the prostaglandin (PG) production of the uterus (Smith et al , 1981 a
& b; Willman et al, 1976). Endometrium from women with ovular dysfunctional
uterine bleeding synthesises more PGE2 than that of normal women, and markedly
enhances the myometrial production of PGI2. (PGI2 or prostacyclin, a
vasodilatory substance, and the most potent inhibitor of platelet aggregation
yet discovered (Moncada & Vane, 1980), is converted to 6oxo PGF, ^ , which is the
major product synthesised when arachidonic acid is incubated with rat or sheep
uteri (Jones et al, 1977)). In women with anovular dysfunctional bleeding,
excessive menstrual loss is associated with a relative deficiency of PGF2 <
synthesis (Smith et al, 1982). There is in fact an inverse relationship between
the ratio of PGF2a(: PGE2 and the amount of blood lost, and it may be, therefore,
that menstrual loss is determined by the relative synthesis of prostaglandins
with mainly vasoconstrictor properties on the one hand (PGF2o(J as opposed to
those with vasodilatory properties (PGE2, PGI2) on the other (Baird et al,
1981).
This manuscript presents further evidence suggesting a role for the




Fifty parous women were recruited for study from the Gynaecological Out
Patient Department of the Royal Infirmary, Edinburgh. All suffered from
rnenorrhagia, diagnosed subjectively, for which no organic cause had been found.
Recruits were instructed to collect their soiled sanitary protection for two
cycles, in order to assess their menstrual loss objectively, and they were also
asked to collect early morning urine samples three times weekly, for total
oestrogen and pregnanediol estimation. In addition, an endometrial biopsy was
performed on 13 women in the mid-luteal phase of the second cycle, in order to
measure endometrial prostaglandin concentrations. These biopsies were performed
without anaesthesia, using a Sharmann Curette.
Written informed consent was obtained from all women, and approval for the
study was granted by the Ethical Sub-Committee in Reproductive Medicine.
Measurement of Menstrual Blood Loss
Menstrual blood loss was assessed objectively using a modification of the
alkaline haematin method of Hallberg & Nilsson (1964). Soiled pads and tampons
were placed in molar NaOH and thoroughly mixed. 24 hours later, an aliquot was
taken, and after filtration, its optical density was measured. Menstrual blood
loss was then calculated by comparing this with the optical density of a
peripheral blood sample, similarly processed. The diagnosis of menorrhagia was
made if the menstrual blood loss exceeded 50 mis per cycle.
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Tissue Collection and Prostaglandin Measurement
Endometrial biopsies were collected on ice into modified 199 medium
(Flow Laboratories, U.K.). After transport to the laboratory within 5
minutes, the tissue was blotted dry on a gauze swab, weighed, and immediately
placed in ice cold ethanol. The tissue was then homogenised using a polytron
homogeniser, and centrifuged at 1500 g for 10 minutes at 4°C. The supernatant
was aspirated, dried under nitrogen, and stored at -20°C, until assayed.
Endogenous concentrations of endometrial prostaglandins were measured using
standard radioimmunoassay techniques (see Abel et al, 1980). Antibodies
raised against PGEg and PGF2< (Dr J. Hennam, Kings College, London) and 6oxo
PGF,©C (Dr J.A. Salmon, Wellcome Research Laboratories, Beckenham) were employed -
and as the antibody against PGE2 cross reacted significantly with PGE( , the value
for the concentration of PGE presented includes prostaglandin from both the 1
and 2 series. Inter and intra assay coefficients of variation, taken over 10
sequential assays and in duplicate 10 times within the same assay, were 12.2%
and 14.4% for PGF2< , and 10.1% and 11.2% for PGE. The intra assay coefficient
of variation for 6oxoPGF(ok was 14.5%.
Combined Incubations of Endometrium and Myometrium.
A further 6 women suffering from benign uterine disease were admitted for
abdominal hysterectomy .in the luteal phase of the cycle. At operation, samples
of both endometrium and myometrium were placed in ice-cold 199 medium and
transported to the laboratory. After blotting and weighing both types of
tissue, a myometrial homogenate was prepared in 199 medium, at a final
concentration of 10mg/ml. Thereafter, small pieces of endometrium (approx.
5mg) were placed in either 1ml of 199 medium or 1 ml of the myometrial homogenate,
and these samples were incubated at 37°C in a water bath for 1 hour, with gentle
shaking. 1 ml samples of the myometrial homogenate alone, and control samples
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of 199 medium we re also processed in similar fashion. Following the incubation,
the pieces of endometrium were removed, and the samples were stored at -20°C
until assayed. Prostaglandin measurement by radioimmunoassay was performed as
previously detailed.
Endometrial Dating
In all experiments, a portion of endometrium was placed in formol saline for
histological dating (Noyes et al, 1950). The occurrence of ovulation was
indicated by the presence of secretory endometrium, along with a
pregnanediol/creatinine ratio greater than 1.0 mg/gm in the early morning urine
specimens.
Statistical Analysis
Non parametric statistical tests were employed (Siegel, 1956). Significance
between independent samples was assessed by the Wilcoxon rank sum test, and
correlation analysis was performed using the Spearman rank correlation test.
RESULTS
Patient Characteristics and Menstrual Blood Loss
Of the 50 women recruited for menstrual blood loss assessment, 2 became
menopausal during the study and a further 3 failed to collect their soiled
sanitary protection adequately. The measured blood loss of the remaining 45
women is shown in Figure 1. It can be seen that there was a wide range of
menstrual losses, and that in this selection of women, all with a subjective
complaint of menorrhagia, almost 50% actually experienced a monthly blood loss
of 1 ess than 50 mls.
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The characteristics of the two groups of women (ie. those with and without
objective menorrhagia) are presented in Table 1. There was no difference
between the groups in terms of age or parity, nor were there differences in the
duration of bleeding or cycle length. Although the mean haemoglobin
concentration of the menorrhagic group was significantly lower than that of the
other group, the value of 12.6 + 0.2 g/dl was well within the range of
normality. Furthermore, there was no compensatory increase in bone marrow
turnover, as indicated by the reticulocyte count, to explain the normal
haemoglobin concentration in the women with heavy blood loss.
As regards ovarian function, most of the women in both groups exhibited
ovular menstrual cycles (Table 1).
Endometrial Prostaglandin Concentrations
The relationship between the endometrial prostaglandins and objectively
assessed menstrual blood loss is indicated in Figure 2. This reveals that there
was a significant correlation between the degree of menstrual blood loss and
both PGE and PGF2<^(p < 0.02 and p < 0.05 respectively). Although there was an
increase in endometrial 6oxoPGF ^concentration in relation to menstrual loss,
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this relationship did not reach statistical significance. However, the "total"
prostaglandin concentration (PGE + PGF2*( + 6oxoPGF j) did correlate with the
degree of blood loss (p < 0.05).
Combined Endometrium and Myometrium
The characteristics of the 6 patients are seen in Table 2. All were in the
secretory phase of the cycle, and all showed luteal function both histologically
and biochemically. Each of the women complained of heavy periods, with
concomitant dysmenorrhoea in 2 cases, however, their menorrhagia was not
assessed objectively.
Endometrial prostaglandin production, both alone and in combination
with myometrium, is presented in Figure 3. After correcting for the
production of prostaglandin by the myometrial homogenate alone, the value for
the combined incubate is expressed in pg/mg endometrium per hour. As can be
seen, there was an increase in the production of GoxoPGFv by the endometrium
when incubated in combination with myometrium, and, in addition, when the
production was expressed as a percentage of "total" prostaglandin this
increase in 6oxoPGF(«< was associated with a significant decrease in the
proportion of PGE formed.
DISCUSSION
The principle of objective assessment is fundamentally important in
scientific research, and this principle is well illustrated when considering
the problem of menorrhagia. In the present study 19 (42%) of 45 women with
a subjective complaint of heavy menses had a measured blood loss of less than
50 mis, and similar results have been found elsewhere (I.S. Fraser and R.
Markham, personal communication). Furthermore, there was no difference in
the duration of bleeding or cycle length in women with heavy periods compared
with those with a normal blood loss, and this again serves to highlight the
pitfalls associated with defining menorrhagia on a purely subjective basis.
The figure of 50mls as the upper limit of normal is taken from a previous
study assessing the blood loss of a group of patients without menstrual abnor¬
mality, who were presenting for laparoscopic sterilisation (Smith et al, 1983).
Other workers have used 80mls as the "cut-off" point, based on the data of
Hallberg et al. (1956), who found that this degree of blood loss represented
the upper 10th centile of the menstrual blood loss range in a large population,
and that this was the level at which iron deficiency problems began to emerge.
Although it might be thought that defining the level of menorrhagia at 50 mis
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rather than 80 mis could introduce a "masking effect", thereby accounting for
the mean haemoglobin concentration in our menorrhagic group, this was not
found to be the case, for the mean haemoglobin concentration in those women
in the present study with a blood loss greater than 80 mis, was also within
normal limits (12.3 ± 0.3 g/dl, n =13).
16% of the low blood toss group and 12% of the menorrhagic women had
anovular cycles. This would agree with the previously cited data that the
pattern of ovarian steroid secretion is normal in the majority of women
suffering from menorrhagia (Haynes et al, 1979).
A relationship between menstrual blood loss and the vasodilatory PGE,
reflected by an increase in the PGE:PGF2c< ratio in menorrhagic women, has
been suggested by a number of studies (Baird et al, 1981; Smith et al 1983),
and the present results showing a correlation between this prostaglandin and
the degree of menstrual loss would further support this idea. On the other
hand, the finding that menstrual loss is also correlated with PGF2<and "total"
PG would appear to be at variance with the hypothesis of a balance mechanism
between the vasoconstrictory and vasodilatory prostaglandins.
The precise relationship between the prostaglandins and menstrual loss is
not yet clear - Rees, for example, has reported an increase in the ratio of PGF?o(:
PGE in the menstrual fluid of women suffering from menorrhagia (Rees, 1983).
Without doubt, great care must be taken when comparing the results of different
studies, due to many variable factors such as patient recruitment, tissue
collectionand experimental methods, nevertheless, the suggestion that menstrual
blood loss might be related to total endometrial prostaglandin concentration is in
fact an attractive one. It would provide a logical explanation for the finding
that menstrual loss is improved in some women by the indiscriminate inhibition of
both the vasodilatory and vasoconstrictory prostaglandins, by the use of cyclo-
g
oxygenase inhibitors such as mefenamic acid (Anderson et al, 1976), and in
addition, recent work has shown that there is an increased availability of
arachidonic acid, and therefore, presumably prostaglandin, in the endometrium
of women with monorrhagia (Kelly et al, 1984).
It has previously been demonstrated that the endometrium from women with
menorrhagia has a greater capacity than normal endometrium to generate 6oxoPGF< ,
when incubated in combination with control myometrium (Smith et al, 1981b).
This increased 6oxoPGF.< production was shown by incubating the tissues with
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exogenous precursor in the form of C- labelled arachidonic acid. In our
experiments, combinations of endometrium and myometrium from the same patients
were tested, with the endometrium itself acting as the source of precursor.
There was an increase in 6oxoPGF«k production when the tissues were incubated
together, suggesting that the endometrium could provide precursor endoperoxide
for prostaglandin production by the myometrium. As the major product of the
arachidonic acid cascade in the myometrium is PGI2 , the physiological result of
delivering such precursor to the myometrium would be an increase invasodilata-
tion and a decrease in platelet aggregation, and both of these mechanisms might
favour increased menstrual loss.
The variable degree by which the 6oxoPGF.»4 production increased in the
present experiments might have been related to the level of menstrual loss,
however, further studies recruiting women with objectively assessed periods
would be necessary to test this hypothesis.
In conclusion, the possible inter-relationships between the prostaglandins
and the uterine vasculature are summarised in Figure 4. The stimulus that
initiates menstruation could lead to the liberation of free arachidonic acid,
presumably via phospholipase activation, and the arachidonic acid in turn
could be converted into the various prostaglandins via the cyclo-oxygenase
pathway. The resultant balance between the pharmacological actions of these
prostaglandins might play a part in the control of the endometrial and
myometrial vessels, and therefore the degree of menstrual blood loss. However,
if excess free arachidonic acid were released, and thus increased precursor
endoperoxide available, not only might the synthetic pathway towards PGF2l?(
(via PGF reductase) become saturated, leading to a diversion of endoperoxide
towards PGE non-enzymatically, but also more PGI2 could be formed, both in the
endometrium and, in addition, in the large muscle mass of the myometrium. This
increase in prostacyclin production could have important implications in the
pathogenesis of menorrhagia.
The prostaglandins would appear to play a part, at least in some women,
in the processes associated with menstrual bleeding, although other events,
such as fibrinolysis, may also have a role. It is hoped that a better
understanding of the mechanism underlying the menses might lead to a more
rational approach to the clinical management of menstruation and its disorders.
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Fiaure 1. Menstrual blood loss distribution.
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Figure 2. The relationship between menstrual blood loss and the endometrial
concentration of (a) PGE and (b) PGF. «<.
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Figure 3 Combined endometrial - myometrial incubations (a) Prostaglandin production
in pg/mg/hr. (b) Prostaglandin production as a percentage of "total"











Figure fl. Endometrial prostaglandins and the uterine vasculature. (Adapted and
redrawn from Eaird et al, 1981, with permission).
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Table 1. Patient characteristics. Values are given as mean 1 standard error.
(*p<0.01, **p<0.001)
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AGE(yrs) PARITY CYCLE DAY
1 46 3+0 4/28 22
2 43 1+0 8/25 26
3 46 4+2 8/26 25
4 35 4+1 11/24 24
5 40 2+0 7/23 22
6 40 4+0 6/21 17
Table 2. Patient characteristics: endometrial - myometrial incubation studies.
